Source: Proactive Investors

PhagoMed Biopharma: PhagoMed Biopharma uses technology to find alternative to antibiotics

PhagoMed Biopharma GmbH CEO Alexander Belcredi sat down with Christine Corrado with Proactive Investors at the 11th Annual BioTech Showcase in San Francisco. The privately-held biotech specializes in developing therapeutics uses for phage therapy, which uses lytic bacteriophages, a virus that infects bacteria, to treat multi-drug resistant bacterial infections.

Read full article »
PhagoMed Biopharma's Competitors | PhagoMed Biopharma's News | PhagoMed Biopharma's Financials
Stay up-to-date with the latest news on PhagoMed
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Alexander Belcredi's photo - Managing Director & CEO of PhagoMed

Managing Director & CEO

Alexander Belcredi

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on PhagoMed